Introduction {#Sec1}
============

Lymphomas are a heterogeneous group of malignancies that account for \~3--4% of cancers worldwide^[@CR1]^. Non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) are histologically and genetically diverse, and may originate from either B- or T-lymphocytes^[@CR2],[@CR3]^. Autoimmune conditions, which affect \~3% of the general population^[@CR4]^, are an established risk factor for lymphoma, conferring \~2- to 37-fold increased risk^[@CR5]--[@CR12]^. Although there are over 80 autoimmune conditions, they can be broadly classified as primarily mediated by B-cell responses or T-cell responses, acknowledging some overlap^[@CR13]--[@CR16]^. Representative B-cell-mediated autoimmune diseases include rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), and representative T-cell-mediated diseases include celiac disease and ulcerative colitis.

In a large pooled analysis from the International Lymphoma Epidemiology Consortium (InterLymph) of 17,471 NHL cases and 23,096 controls, autoimmune conditions classified as primarily mediated by B-cell responses were associated with an increased risk of lymphoma, particularly diffuse large B-cell lymphoma (DLBCL) and marginal zone lymphoma (MZL), whereas autoimmune conditions classified as primarily mediated by T-cell responses were only associated with risk of T-cell lymphoma (TCL)^[@CR10]--[@CR12],[@CR17]^. In contrast to lymphoma etiology, relatively few studies have evaluated the relationships between history of autoimmune conditions with lymphoma prognosis^[@CR18]--[@CR24]^, which may have implications for clinical management. We evaluated lymphoma subtype-specific outcomes by autoimmune history overall, as well as classified as autoimmune conditions primarily mediated by B-cell responses or T-cell responses in a prospective cohort study with detailed clinical, treatment, and outcome data.

Methods {#Sec2}
=======

We used Mayo Clinic cases enrolled in the University of Iowa/Mayo Clinic SPORE Molecular Epidemiology Resource, a prospective cohort study that has been previously described^[@CR25]^. Briefly, consecutive patients with lymphoma were prospectively approached within 9 months of diagnosis for enrollment. Pathology was centrally reviewed and classified according to the World Health Organization^[@CR26]^. Clinical and treatment data were abstracted using standard protocols, and participants were contacted every 6 months for the first 3 years, then annually to ascertain disease recurrence or progression, new treatments, transformation, and new cancer diagnoses. All events were validated against medical records.

All participants provided written informed consent and the cohort protocol was approved by the institutional review boards at the Mayo Clinic.

Participants enrolled at Mayo Clinic from 2002--2015 with self-reported risk factor data on 8 autoimmune diseases were eligible for the current analysis, which included 736 DLBCL, 703 follicular lymphoma (FL), 302 MZL, 193 mantle cell lymphoma (MCL), 297 HL, and 186 TCL patients. Autoimmune conditions were categorized as either primarily mediated by B-cell responses \[RA, Sjögren syndrome (SS), SLE, and Hashimoto thyroiditis\] or T-cell responses \[celiac disease, Crohn's, ulcerative colitis, and polymyositis/dermatomyositis\] according to the InterLymph classification^[@CR27]^.

The *χ*^2^-test was used to calculate associations between overall autoimmune conditions and lymphoma patients' clinical characteristics such as sex, age, Eastern Cooperative Oncology Group (ECOG) performance status, and prognostic index. We defined event-free survival (EFS) as time from diagnosis to progression/relapse, re-treatment, or death, and overall survival (OS) as time from diagnosis to death due to any cause. We used Cox proportional hazards regression analysis to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) to test the association between autoimmune conditions and EFS and OS, adjusting for sex and the following subtype-specific variables: International Prognostic Index (IPI)^[@CR28]^ for DLBCL, MZL, and TCL; Mantle Cell IPI (MIPI)^[@CR29]^ for MCL; International Prognostic Score (IPS)^[@CR30]^ for HL; FLIPI^[@CR31]^, FL grade III, and treatment (observation, rituximab monotherapy, immunochemotherapy, and other therapy**)** for FL; and treatment \[immunochemotherapy (anthracyline based) vs. other\] for DLBCL. In additional modeling, we also adjusted for presence of any of seven selected comorbidities (other cancer diagnosis within 3 years of lymphoma diagnosis \[excluding non-melanoma skin cancer\], coronary heart disease, congestive heart failure, diabetes, hip fracture, hepatitis, and elevated creatinine) and smoking status (never, former, and current). Finally, to estimate the association of autoimmune disease across all six lymphoma subtypes for EFS and OS, we conducted a meta-analysis using the fixed-effects method. We calculated Cochran's *Q*-statistic to test for heterogeneity across lymphoma subtypes and the *I*^2^ statistic to quantify the proportion of the total variation due to heterogeneity.

Results {#Sec3}
=======

Clinical characteristics are presented in Table [1](#Tab1){ref-type="table"}. Male gender was most prevalent in MCL (77.2%) and least prevalent in MZL (47.4%), and the percent of cases older than 60 years was the highest for MCL (63.7%) and lowest for HL (20.9%) as expected (Table [1](#Tab1){ref-type="table"}). At a median follow-up of 5.9 years (range, 0.02--14.1 years), 1071 participants (44.6%) had an event and 613 participants (25.6%) had died.Table 1Demographic and clinical characteristicsSubtypeCovariateCategory*N*%DLBCL *N* = 736SexMale41356.1%Age, years\>6043258.7%IPI0 - Low risk8812.0%1 - Low risk17423.6%2 - Low-intermediate risk22630.7%3 - High-intermediate risk17724.0%4 - High risk587.9%5 - High risk131.8%PS\<265989.5%≥27710.5%TreatmentImmunochemotherapy66890.8%FL *N* = 703SexMale36151.4%Age, years\>6036051.2%FLIPI0 - Low risk7811.1%1 - Low risk21130.0%2 - Intermediate risk24034.1%3 - High risk13018.5%4 - High risk375.3%5 - High risk71.0%PS\<268797.7%≥2162.3%FLIIINo60185.5%Yes10214.5%TreatmentObservation24935.4%R monotherapy8912.7%Immunochemotherapy27238.7%Other chemotherapy9313.2%MZL *N* = 302SexMale14347.4%Age, years\>6016655.0%IPI0 - Low risk7524.8%1 - Low risk12140.1%2 - Low-intermediate risk7123.5%3 - High-intermediate risk3210.6%4 - High risk31.0%5 - High risk00.0%PS\<229898.7%≥241.3%MCL *N* = 193SexMale14977.2%Age, years\>6012363.7%MIPILow risk (0--3)8041.5%Interm/high risk (4--12)11358.5%PS\<218193.8%≥2126.2%HL N = 297SexMale15552.2%Age, years\>606220.9%IPS0 - Low risk1.3%1 - Low risk4715.8%2 - Low risk11639.1%3 - Intermediate risk8127.3%4 - Intermediate risk3511.8%5 - High risk124.0%6 - High risk51.7%PS \< 228094.3% ≥ 2175.7%TCL *N* = 168SexMale10461.9%Age, years \> 607745.8%IPI0 - Low risk3319.6%1 - Low risk4526.8%2 - Low-intermediate risk4526.8%3 - High-intermediate risk2917.3%4 - High risk158.9%5 - High risk1.6%PS \< 214686.9% ≥ 22213.1%Abbreviations: *DLBCL* diffuse large B-cell lymphoma, *FL* follicular lymphoma, *FLIPI* Follicular Lymphoma International Prognostic Index, *FLIII* follicular lymphoma grade 3*, HL* Hodgkin lymphoma, *IPI* International Prognostic Index, *MCL* mantle cell lymphoma, *MIPI* Mantle Cell International Prognostic Index, *MZL* marginal zone lymphoma, *PS* performance status, *TCL* T-cell lymphoma

The prevalence of any of the eight self-reported autoimmune conditions varied across subtypes and was highest in MZL (18.2%), followed by DLBCL (12.2%), TCL (11.9%), MCL (10.4%), FL (9.1%), and HL (7.4%). Autoimmune conditions primarily mediated by B-cell responses were more prevalent than autoimmune conditions primarily mediated by T-cell responses in DLBCL (9.0% vs. 4.1%), FL (6.1% vs. 4.0%), MZL (14.9% vs. 4.0%), and MCL (5.7% vs. 4.7%), similar in HL (4.0% vs. 3.7%), whereas autoimmune conditions primarily mediated by T-cell responses were more prevalent than autoimmune conditions primarily mediated by B-cell responses in TCL (7.1% vs. 4.8%). RA was the most common autoimmune condition and was highest in MZL (7.6%), followed by DLBCL (7.2%), FL (4.8%), MCL (4.7%), TCL (3.6%), and HL (3.0%) (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1**Prevalence of autoimmune conditions, B-cell/T-cell-activating autoimmune conditions, and rheumatoid arthritis by lymphoma subtypes**. Abbreviations: *DLBCL* diffuse large B-cell lymphoma, *FL* follicular lymphoma, *HL* Hodgkin lymphoma, *MCL* mantle cell lymphoma, *MZL* marginal zone lymphoma, *TCL* T-cell lymphoma

History of an autoimmune condition was associated with female gender (58.7% with any autoimmune condition vs. 43.0% without autoimmune condition, *P* \< 0.001), age \> 60 years (60.1% with any autoimmune condition vs. 49.7% without autoimmune condition, *P* = 0.001), smoking status (*P* \< 0.001; mainly driven by missing status), and lymphoma subtype (*P* \< 0.001; strongest for MZL), but was not associated with ECOG performance status ≥ 2 (8.1% with any autoimmune condition vs. 5.9% without autoimmune condition, *P* = 0.16), high prognostic index (10.3% with any autoimmune condition vs. 11.9% without autoimmune condition, *P* = 0.44), or the presence of comorbidities (Table [2](#Tab2){ref-type="table"}).Table 2Clinical characteristics by any autoimmune conditions\*No autoimmune conditionAny autoimmune conditionCharacteristic*N*%*N*%*P*SexMale121357.0%11241.3% \< 0.001Female91543.0%15958.7%Age ≤ 60 Years107150.3%10839.9%0.001 \> 60 Years105749.7%16360.1%Performance Status \< 2200294.1%24991.9%0.16 ≥ 21265.9%228.1%Prognostic IndexLow-intermediate risk187488.1%24389.7%0.44High risk25411.9%2810.3%ComorbiditiesNo154372.5%17966.1%0.08Yes23711.1%3814.0%Missing34816.4%5419.9%SmokingNever97145.6%11943.9% \< 0.001Former54225.5%9434.7%Current1607.5%269.6%Missing45521.4%3211.8%SubtypeDLBCL64630.4%9033.2% \< 0.001FL63930.0%6423.6%MZL24711.6%5520.3%MCL1738.1%207.4%HL27512.9%228.1%TCL1487.0%207.4%\*Based on self-report. *DLBCL* diffuse large B-cell lymphoma, *HL* Hodgkin lymphoma, *IPI* International Prognostic Index, *MALT* mucosa-associated lymphoid tissue, *MCL* mantle cell lymphoma, *MZL* marginal zone lymphoma, *PS* performance status, *TCL* T-cell lymphoma

There was no evidence of an association of history of any autoimmune condition as a group with EFS or OS for any lymphoma subtype (Table [3](#Tab3){ref-type="table"} and Figs. [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}). However, there were positive associations of autoimmune conditions primarily mediated by B-cell responses with inferior EFS in MCL (HR = 2.23, 95% CI 1.15--4.34) and HL (HR = 2.63, 95% CI 1.04--6.63), which was largely driven by RA, the most common autoimmune condition. Similar associations with OS were seen in MCL (HR = 1.69, 95% CI 0.80--3.56) and HL (HR = 2.84, 95% CI 0.85--9.47), but these were not statistically significant; there was also a trend toward inferior OS for DLBCL (HR = 1.41, 95% CI 0.95--2.08).Table 3Multivariable-adjusted hazard ratios for any autoimmune conditions, B-cell/T-cell-activating autoimmune conditions, and rheumatoid arthritis by lymphoma subtypePrevalence of autoimmune conditionEvent-free survivalOverall survivalEventsEventsAdjustment factors*N*%*N*%HR95% CI*pN*%HR95% CI*p*DLBCL (*N* = 736)No autoimmune conditionSex, IPI, treatment\*64628644.31.00Reference21533.31.00ReferenceAny autoimmune condition9012.24448.91.140.83--1.570.423336.71.140.79--1.640.49B-cell responses669.03553.01.260.88--1.790.202943.91.410.95--2.080.09Rheumatoid arthritis537.22852.81.150.78--1.690.492445.31.330.87--2.030.18T-cell reponses304.11240.00.890.50--1.590.70723.30.730.34--1.550.41FL (*N* = 703)No autoimmune diseaseSex, FLIPI, FLIII, treatment\^63933252.01.00Reference11017.21.00ReferenceAny autoimmune condition649.12945.30.880.59--1.290.501218.81.370.74--2.500.32B-cell activating436.11944.20.870.54--1.390.55716.31.130.52--2.460.76Rheumatoid arthritis344.81544.10.880.52--1.480.62617.61.220.53--2.800.64T-cell activating284.01242.90.740.42--1.330.32517.91.300.52--3.220.58MZL (*N* = 302)No autoimmune conditionSex, IPI2478835.61.00Reference3514.21.00ReferenceAny autoimmune condition5518.21934.51.050.63--1.750.85610.90.790.33--1.910.79B-cell activating4514.91533.31.010.58--1.760.9848.90.600.21--1.720.34Rheumatoid arthritis237.6939.10.990.49--2.000.98313.00.620.19--2.080.44T-cell activating124.0650.01.800.78--4.180.17325.02.500.76--8.240.13MALT (*N* = 219)No autoimmune conditionSex, IPI1735934.11.00Reference1810.41.00ReferenceAny autoimmune condition46211634.81.380.77--2.490.2936.51.080.30--3.800.91B-cell activating3917.81333.31.330.71--2.490.3725.10.860.19--3.820.84Rheumatoid arthritis188.2738.91.390.64--3.040.4115.60.730.10--5.520.76T-cell activating83.7450.01.800.64--5.070.26112.51.830.24--14.10.56MCL (*N* = 193)No autoimmune conditionSex, MIPI17310560.71.00Reference7744.51.00ReferenceAny autoimmune condition2010.41470.01.130.64--1.980.681050.00.940.49--1.830.94B-cell activating115.71090.9**2.231.15--4.340.02**872.71.690.80--3.560.17Rheumatoid arthritis94.7888.9**2.531.22--5.280.01**666.71.460.63--3.400.38T-cell activating94.7444.40.490.18--1.340.17222.20.350.09--1.410.35HL (*N* = 297)No autoimmune conditionSex, IPS2755319.31.00Reference3312.01.00ReferenceAny autoimmune condition227.4731.81.660.75--3.670.21418.21.310.46--3.720.61B-cell activating124.0541.7**2.631.04--6.630.04**325.02.840.85--9.470.09Rheumatoid arthritis93.0444.42.510.90--6.990.08333.33.290.99--10.90.05T-cell activating113.7218.20.760.18--3.110.719.10.460.06--3.400.45TCL (*N* = 168)No autoimmune conditionSex, IPI1488255.41.00Reference6845.91.00ReferenceAny autoimmune condition2011.91260.01.620.88--2.990.121050.01.460.74--2.860.28B-cell activating84.8562.51.540.62--3.810.35450.01.130.41--3.110.81Rheumatoid arthritis63.6350.00.990.31--3.150.99350.00.900.28--2.880.86T-cell activating127.1758.31.600.73--3.500.24650.01.720.74--4.020.21Abbreviations: *CI* confidence interval, *DLBCL* diffuse large B-cell lymphoma, *FL* follicular lymphoma, *FLIPI* Follicular Lymphoma International Prognostic Index, *FLIII* follicular lymphoma grade 3, *HL* Hodgkin lymphoma, *HR* hazard ratio, *IPI* International Prognostic Index, *IPS* International Prognostic Score, *MALT* mucosa-associated lymphoid tissue, *MCL* mantle cell lymphoma, *MIPI*, Mantle Cell International Prognostic Index, *MZL* marginal zone lymphoma, *TCL* T-cell lymphoma\*Immunochemotherapy vs. all other therapy. \^Rituximab-based therapy, other chemotherapy vs. observation.Bold would be considered statistically significantFig. 2**Overall survival for any autoimmune conditions, B-cell/T-cell-activating autoimmune conditions, and rheumatoid arthritis**. Abbreviations: *CI* confidence interval, *DLBCL* diffuse large B-cell lymphoma, *FL* follicular lymphoma, *MZL* marginal zone lymphoma, *HL* Hodgkin lymphoma, *HR* hazard ratio, *I*^2^ statistic to quantify the proportion of the total variation due to heterogeneity, *MCL* mantle cell lymphoma, *P*~het~ test for heterogeneity across lymphoma subtypes, *Q* Cochran's *Q*-statistic, *TCL* T-cell lymphoma. **a** Association between overall survival and any autoimmune disease across lymphoma subtypes. **b** Association between overall survival and autoimmune conditions primarily mediated by B-cell responses across lymphoma subtypes. **c** Association between overall survival and autoimmune conditions primarily mediated by T-cell responses across lymphoma subtypes. **d** Association between overall survival and rheumatoid arthritis across lymphoma subtypesFig. 3**Event-free survival for any autoimmune conditions, B-cell/T-cell activating autoimmune conditions, and rheumatoid arthritis**. Abbreviations: *CI* confidence interval, *DLBCL* diffuse large B-cell lymphoma, *FL* follicular lymphoma, *HL* Hodgkin lymphoma, *HR* hazard ratio, *I*^*2*^ statistic to quantify the proportion of the total variation due to heterogeneity, *MCL* mantle cell lymphoma, *MZL* marginal zone lymphoma, *P*~het~ test for heterogeneity across lymphoma subtypes, *Q* Cochran's *Q*-statistic, *TCL* T-cell lymphoma. **a** Association between event-free survival and any autoimmune disease across lymphoma subtypes. **b** Association between event free survival and autoimmune conditions primarily mediated by B-cell responses across lymphoma subtypes. **c** Association between event-free survival and autoimmune conditions primarily mediated by T-cell responses across lymphoma subtypes. **d** Association between event free survival and rheumatoid arthritis across lymphoma subtypes

To further address potential confounding by comorbidity or smoking status, we re-ran models in Table [3](#Tab3){ref-type="table"} that included both of these variables. After these further adjustments, we observed slightly stronger associations of autoimmune conditions primarily mediated by B-cell responses with inferior EFS in MCL (HR = 2.36, 95% CI 1.17--4.75) and HL (HR = 2.73, 95% CI 1.06--7.04), which was largely driven by RA for both MCL (HR = 3.08, 95% CI 1.39--6.82) and HL (HR = 2.73, 95% CI 0.92--7.47), whereas similar associations were observed with OS for both MCL (HR = 1.71, 95% CI 0.77--3.77) and HL (HR = 3.05, 95% CI 0.88--10.6). Results for all other subtypes in Table [3](#Tab3){ref-type="table"} were not changed by these adjustments (data not shown).

Autoimmune conditions primarily mediated by T-cell responses were not associated with EFS or OS for any subtype, although the number of events was generally small for this exposure.

Discussion {#Sec4}
==========

Although we found no overall association of any autoimmune disease as a group with prognosis for individual lymphoma subtypes, we did find that a history of autoimmune conditions primarily mediated by B-cell responses were associated with inferior EFS for MCL and HL, and that this was largely driven by RA. The latter associations showed similar but not statistically significant trends with OS. Although autoimmune conditions primary mediated by T-cell responses were not associated with any of the lymphoma subtypes, these analyses were challenged by the low prevalence of these types of autoimmune diseases.

Strengths of this study include the following: the prospective study design; central pathology review; use of the InterLymph autoimmune classification^[@CR27]^; availability of high-quality clinical and outcome data, including both EFS and OS; and adjustment for subtype-specific prognostic factors, as well as comorbidity and smoking status. Limitations of our study include the following: self-reported data for autoimmune conditions; ascertainment of only eight types of autoimmune conditions, whereas there are \~80 types of autoimmune diseases; and likely limited power to assess some associations, particularly for autoimmune conditions primarily mediated by T-cell responses and for OS. Self-reported autoimmune conditions can lead to exposure misclassification, although a case--control study from InterLymph that used self-reported data for autoimmune conditions found a good concordance between control prevalence with population prevalence from different countries, except for RA and ulcerative colitis, which were higher than published prevalence estimates^[@CR17]^. The prevalence of RA in our DLBCL cases (7.2%) was also higher than the prevalence reported by study using Surveillance, Epidemiology, and End Results (SEER)-Medicare data (2.6%)^[@CR23]^, but it is not clear if this is a function of differences in study design, study population characteristics, or over-reporting of these conditions in our study. Our study was also not able to capture measures of severity of autoimmune conditions, treatment for autoimmune conditions, adjustments to lymphoma-directed therapy based on autoimmune disease status (including curative intent in aggressive lymphomas), nor use of more recent immune therapies such as CAR-T and immune checkpoint inhibitors, all of which may have an impact on lymphoma prognosis and are important unaddressed needs for future research.

Our findings are supported in part by other studies, although findings from the small number of studies published to date are not consistent. A population-based cohort study of 1523 Swedish NHL patients with a median follow-up of 8.8 years, found a 1.4-fold increased risk of death among NHL cases with autoimmune conditions compared with those without autoimmune conditions, which included both B-cell- and T-cell-mediated autoimmune conditions (RA, SS, SLE, and celiac disease); however, they did not find an association with subtype-specific lymphomas including DLBCL, FL, MCL, or TCL^[@CR18]^. An Israeli study of 435 B-cell NHL cases with a median follow-up of 3.5 years found a 1.69-fold increased risk of relapse among cases with any autoimmune conditions, which included both B-cell- and T-cell-mediated autoimmune conditions, and a 3.41-fold increased risk of relapse among cases with autoimmune conditions primarily mediated by B-cell responses when compared with patients without autoimmune conditions^[@CR24]^. Another Swedish study examined the impact of concomitant RA on cause-specific survival and OS among 329 NHL and 60 HL patients, and reported a 1.43-fold increased risk for cause-specific survival among RA cases with NHL, and a 1.41-fold and 1.33-fold increased risk of death among RA cases with NHL and HL, respectively^[@CR19]^. Our study differed from the Swedish study by collecting autoimmune status by patient self-report as opposed to registry data.

Conversely, a study using the Nebraska Lymphoma Study Group and the Mayo Clinic Lymphoma Database registries of 1595 NHL patients found that RA was associated with improved NHL-related outcomes, with a 40% reduced risk of death and a 60% lower risk of lymphoma relapse or progression compared with non-RA NHL patients; however, patients with concomitant RA and NHL were more than twice as likely to die from causes unrelated to lymphoma^[@CR20]^. A study in Taiwan retrospectively reviewed 913 medical records of newly diagnosed lymphoma patients and found that pre-existing autoimmune diseases, which included B-cell- and T-cell-mediated autoimmune diseases, and other thyroid autoimmune diseases, were not associated with inferior progression-free survival or OS^[@CR22]^. A study using the SEER database with 5926 DLBCL patients, examined survival patterns in DLBCL cases with RA, SLE, SS, and other B-cell-mediated autoimmune diseases, and found no significant difference compared to patients with no history of these diseases^[@CR23]^. In addition, a study from the University of Iowa/Mayo Clinic Molecular Epidemiology Resource found that a history of immunosuppression did not affect subsequent prognosis in DLBCL cases, although it is known to be a risk factor for the development of DLBCL.^[@CR32]^ The latter finding aligns with our DLBCL survival findings and the Swedish findings^[@CR18]^, although we did see a trend towards inferior survival in DLBCL patients with autoimmune conditions primarily mediated by B-cell responses.

In contrast, in the Israeli study, autoimmune conditions primarily mediated by B-cell responses compared to those without autoimmune conditions primarily mediated by B-cell responses were associated with an increased risk of relapse (HR = 3.83; 95% CI: 1.20--12.3) and death (HR = 8.34; 95% CI: 3.01--23.1) in 182 patients with DLBCL and an increased risk of relapse (HR = 13.4; 95% CI: 2.48--72.6) in 65 patients with MZL.^[@CR24]^ However, autoimmune conditions were relatively rare in this study, which explains the imprecise CIs. In addition, there was some evidence in our study of a positive trend between autoimmune conditions primarily mediated by T-cell responses and EFS and OS for TCL, although it was not statistically significant.

Integrating these findings with the etiology findings from the InterLymph pooled case--control analyses, which found that specific NHL subtypes are associated with distinct autoimmune diseases, supports the hypothesis that there are likely to be subtype-specific mechanisms of lymphomagenesis, mechanisms that have yet to be elucidated but which may provide new biologic insights^[@CR10]--[@CR12],[@CR17]^. For example, our data suggest that there may be a mechanism involving lymphomas originating from B-lymphocytes, specifically MCL, HL, and perhaps DLBCL, and autoimmune conditions primarily mediated by B-cell responses, and lymphomas originating from T-lymphocytes, specifically TCL, and autoimmune conditions primarily mediated by T-cell responses in terms of lymphoma pathogenesis and prognosis.

Alternately, it has been proposed that the level of inflammation and severity of the autoimmune condition may contribute to increased risk of lymphoma development. Major predisposing factors for lymphoma development include chronic activation or stimulation of B-cells or T-cells, and the type of autoimmune condition involved in lymphoma pathogenesis is likely disease-specific^[@CR33]^. For example, aggressive systemic inflammation in RA cases increases chronic activation of peripheral B-cells that in turn may increase clonal B-cell populations, which may lead to DLBCL^[@CR33],[@CR34]^. In celiac disease, proliferation of T-cells at the inflammation site may predispose for enteropathy-associated TCL^[@CR33]^. However, less is known about how these possible biological mechanisms may contribute to prognosis once lymphoma developed in patients with autoimmune conditions, which also must incorporate disease activity and ongoing treatment(s) for both the autoimmune disease and the lymphoma, and these are important areas for future research, particularly with new immune-based therapies for the treatment of lymphomas.

Further validation is needed for these findings, and larger sample sizes, such as large institutional studies with high-quality data on autoimmune conditions, including severity and treatment, linked with lymphoma outcomes appear to be warranted to fully understand the role of these diseases in the management of lymphoma patients. Specifically, studies are warranted to replicate our findings for MCL and HL, and perhaps a larger study for TCL that will have enough power to investigate the association of prognosis with autoimmune conditions primarily mediated by T-cell responses.
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